SCHD's annual index reconstitution reshapes dividend strategy.

SCHD's annual index reconstitution reshapes dividend strategy. The Schwab U.S. Dividend Equity ETF completed its March 2026 rebalancing, cutting energy exposure by approximately eight percent while increasing healthcare and technology allocations. Major additions include UnitedHealth, Abbott Laboratories, Procter and Gamble, Qualcomm, and Accenture, while Cisco, AbbVie, Valero Energy, Halliburton, and CF Industries were removed. The fund's trailing price-to-earnings ratio improved modestly, though earnings growth remains a challenge for its components. The index yield held steady at 3.60 percent, reflecting the structural nature of this rebalancing. Investors should consider complementary ETFs to address potential momentum and growth limitations within the current portfolio composition.